Payment overview · 2025
General Payments
$146,935.00
187 reported records · 36 companies
Healthcare provider profile · identity verified
Amit Sachdev, M.D., MS
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · EAST LANSING, MI · NPI 1962720797
Verified facts
What the public records show
CMS Open Payments records show Amit Sachdev, M.D., MS received $146,935.00 in general payments during 2025 across 187 reported records.
Alexion Pharmaceuticals, Inc. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Soliris by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Privigen by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38,893.24 | 26.5% | 35 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $38,838.15 | 26.4% | 37 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28,262.33 | 19.2% | 16 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $18,377.86 | 12.5% | 28 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16,268.92 | 11.1% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $4,358.65 | 3.0% | 12 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $293.18 | 0.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $211.45 | 0.1% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $159.87 | 0.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $148.50 | 0.1% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$105.83 | 0.1% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $91.24 | 0.1% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $87.54 | 0.1% | 3 | 2025 |
| Sarepta Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.00 | 0.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.00 | 0.1% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.56 | 0.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.20 | 0.0% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $57.48 | 0.0% | 2 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $53.83 | 0.0% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$39.21 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.96 | 0.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.38 | 0.0% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $29.90 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $29.15 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.96 | 0.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.14 | 0.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.81 | 0.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.59 | 0.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.46 | 0.0% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.44 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.97 | 0.0% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $20.86 | 0.0% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $19.86 | 0.0% | 1 | 2025 |
| ITF Therapeutics LLC | Unresolved — no canonical attribution shown | $19.51 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $16.39 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,761.50 | 42 |
| Consulting Fee | $27,639.25 | 7 |
| Travel and Lodging | $12,257.15 | 39 |
| Food and Beverage | $4,188.40 | 97 |
| Education | $88.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $28,302.62 | 32 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $24,797.17 | 26 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $11,265.84 | 12 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $9,366.30 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $4,519.25 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $4,100.00 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $3,800.59 | 10 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $558.06 | 2 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $293.18 | 2 | 2025 |
Source payment records
|
|||||
| AGAMREE Normalized: agamree |
Drug | CATALYST PHARMACEUTICALS, INC. | $272.52 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $159.87 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $148.50 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $105.83 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $95.77 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., Octapharma USA, Inc., PFIZER INC. | $87.97 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $87.54 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $79.00 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $63.56 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $62.20 | 2 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $53.83 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $51.75 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC., PFIZER INC. | $40.96 | 2 | 2025 |
Source payment records
|
|||||
| Evrysdi Normalized: evrysdi |
Drug | Genentech USA, Inc. | $39.49 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.96 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Kygevvi Normalized: kygevvi |
Drug | UCB, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $10.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 143 | 40 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 118 | 35 |
| Prednisone | Prednisone | 102 | 30 |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 79 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 73 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 68 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 18 |
| Pregabalin | Pregabalin | 49 | 14 |
| Soliris | Eculizumab | 47 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 43 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | 12 |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 30 | suppressed |
| Baclofen | Baclofen | 29 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 26 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146,935.00 · 187 records | Alexion Pharmaceuticals, Inc. | AGAMREE, AMYVID, Albuked, BOTOX, BRIUMVI, Briviact, CREXONT, DAYBUE, EPIDIOLEX, Evrysdi, FIRDAPSE, Fintepla, GAMMAKED, HYQVIA, Haegarda, Hizentra, INBRIJA, KEDRAB, KESIMPTA, KEVEYIS, KISUNLA, KOATE, Kygevvi, Leqembi, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, PONVORY, QUTENZA, REXULTI, RhoGAM Ultra-Filtered PLUS, Rystiggo, SKYCLARYS, SYMPAZAN, TYSABRI, ULTOMIRIS, UPLIZNA, VALTOCO, VYEPTI, VYVGART, VYVGART HYTRULO, Zilbrysq | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Alexion Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error